Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
92.25
-2.10 (-2.23%)
Feb 21, 2025, 4:00 PM EST - Market closed
Blueprint Medicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 508.82 | 249.38 | 204.04 | 180.08 | 793.74 | Upgrade
|
| Revenue Growth (YoY) | 104.04% | 22.22% | 13.30% | -77.31% | 1093.37% | Upgrade
|
| Cost of Revenue | 20.16 | 12.8 | 26.76 | 25.74 | 0.43 | Upgrade
|
| Gross Profit | 488.66 | 236.58 | 177.28 | 154.35 | 793.31 | Upgrade
|
| Selling, General & Admin | 359.27 | 295.14 | 237.37 | 195.29 | 157.74 | Upgrade
|
| Research & Development | 341.43 | 427.72 | 477.42 | 601.03 | 326.86 | Upgrade
|
| Operating Expenses | 700.71 | 722.86 | 714.79 | 796.33 | 484.6 | Upgrade
|
| Operating Income | -212.04 | -486.28 | -537.52 | -641.98 | 308.71 | Upgrade
|
| Interest Expense | -68.81 | -51.61 | -17.75 | - | - | Upgrade
|
| Interest & Investment Income | 18.19 | 15.35 | - | 3.75 | 7.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.24 | -0.95 | 2 | -1.49 | -0.37 | Upgrade
|
| EBT Excluding Unusual Items | -262.9 | -523.48 | -553.26 | -639.72 | 315.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | 23.37 | 17.47 | 0.98 | -1.36 | -0.47 | Upgrade
|
| Other Unusual Items | 173.68 | - | - | - | - | Upgrade
|
| Pretax Income | -65.86 | -506.02 | -552.28 | -641.08 | 314.94 | Upgrade
|
| Income Tax Expense | 1.23 | 0.97 | 5.24 | 3 | 1.06 | Upgrade
|
| Net Income | -67.09 | -506.98 | -557.52 | -644.09 | 313.88 | Upgrade
|
| Net Income to Common | -67.09 | -506.98 | -557.52 | -644.09 | 313.88 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 61 | 60 | 59 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 61 | 60 | 59 | 56 | Upgrade
|
| Shares Change (YoY) | 3.80% | 1.54% | 1.92% | 4.18% | 17.44% | Upgrade
|
| EPS (Basic) | -1.07 | -8.37 | -9.35 | -11.01 | 5.76 | Upgrade
|
| EPS (Diluted) | -1.07 | -8.37 | -9.35 | -11.01 | 5.59 | Upgrade
|
| Free Cash Flow | -197.22 | -452.91 | -511.2 | -301.74 | 383.88 | Upgrade
|
| Free Cash Flow Per Share | -3.14 | -7.48 | -8.57 | -5.16 | 6.83 | Upgrade
|
| Gross Margin | 96.04% | 94.87% | 86.88% | 85.71% | 99.95% | Upgrade
|
| Operating Margin | -41.67% | -194.99% | -263.44% | -356.50% | 38.89% | Upgrade
|
| Profit Margin | -13.19% | -203.30% | -273.24% | -357.67% | 39.54% | Upgrade
|
| Free Cash Flow Margin | -38.76% | -181.61% | -250.54% | -167.56% | 48.36% | Upgrade
|
| EBITDA | -195.75 | -474.61 | -525.78 | -635.5 | 315.27 | Upgrade
|
| EBITDA Margin | -38.47% | -190.32% | -257.69% | - | 39.72% | Upgrade
|
| D&A For EBITDA | 16.29 | 11.67 | 11.74 | 6.48 | 6.56 | Upgrade
|
| EBIT | -212.04 | -486.28 | -537.52 | -641.98 | 308.71 | Upgrade
|
| EBIT Margin | -41.67% | -194.99% | -263.44% | - | 38.89% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 0.34% | Upgrade
|
| Revenue as Reported | 508.82 | 249.38 | 204.04 | 180.08 | 793.74 | Upgrade
|
| Advertising Expenses | 31.1 | 16.9 | 18.1 | 13.5 | 9.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.